1. Pink Sheet
  2. >>Market Access

Denying Inappropriate PCSK9 Prescriptions Keeps Costs In Check For Express Scripts

 
• By Jessica Merrill

About 50% of the scripts being written for the cholesterol-lowering drugs are being denied, Chief Trade Relations Officer Everett Neville indicated during the Pharmaceutical Strategy Conference.

Express Scripts Holding Co.’s Chief Trade Relations Officer Everett Neville said the pharmacy benefit manager’s approach to managing the new PCSK9 inhibitors – Amgen Inc.’s Repatha and Sanofi/Regeneron Pharmaceuticals Inc.’s Praluent – is very different from its strategy in hepatitis C, where it ended up excluding one firm's product in favor of another.

“Yes, cost is an issue. They are overpriced, but the most important factor with the PCSK9s is that not many...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

EU Pharma Reform: Council Proposal A ‘Step In The Right Direction’ But ‘More Work To Be Done’

 
• By Eliza Slawther

Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.